登录新浪财经APP 搜索【信披】查看更多考评等级 湖南华纳大药厂股份有限公司 注2：本次拟中选药品的采购周期为自中选结果实际执行日起至2028年12月31日。 二、本次拟中选产品对公司的影响 证券代码：688799 证券简称：华纳药厂 公告编号：2026-004 自愿披露关于公司参与国家组织集采药品协议期满 品种接续采购拟中选的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）参加了国家组织集采药品协议期满品种接续采 购办公室（以下简称"接续采购办公室"）组织的国家组织集采药品协议期满品种接续采购（以下简 称"本次接续采购"）。根据接续采购办公室发布的《国家组织集采药品协议期满品种接续采购拟中选结 果公示》，公司部分药品拟中选本次接续采购，现将相关情况公告如下： 一、拟中选产品基本情况 ■ 注1：上述产品最终中选结果、中选价格等以接续采购办公室发布的最终数据为准。 湖南华纳大药厂股份有限公司董事会 2026年2月13日 本次接续采购品种为第1-8批国家组织集采协议期满的 ...

Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including montmorillonite powder, being proposed for selection in this procurement process [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including Montmorillonite Powder, being proposed for selection in this procurement [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - During the procurement cycle, medical institutions will prioritize the use of the selected drugs, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]

证券代码：688799 证券简称：华纳药厂 公告编号：2026-004 湖南华纳大药厂股份有限公司 自愿披露关于公司参与国家组织集采药品协议期满 品种接续采购拟中选的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 注 1：上述产品最终中选结果、中选价格等以接续采购办公室发布的最终数据为准。 注 2：本次拟中选药品的采购周期为自中选结果实际执行日起至 2028 年 12 月 31 日。 二、本次拟中选产品对公司的影响 本次接续采购品种为第 1-8 批国家组织集采协议期满的品种，约定采购量以 医药机构填报各企业采购品种需求量为基数，按照中选价格梯度确定带量比例。 采购周期自中选结果实际执行日起至 2028 年 12 月 31 日。 公司本次拟中选的产品共计 12 个。公司上述拟中选产品 2024 年实现销售收 入为 17,618.05 万元，占公司 2024 年营业收入的 12.47%；2025 年 1-9 月实现销 售收入为 19,205.12 万元，占公司 2025 年 1-9 月营业收入的 17.69%。采购周期 中 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has participated in the national organized procurement for drugs whose agreements have expired, with several of its products expected to be selected in this procurement process [1] Group 1: Procurement Details - The procurement involves products from the first to the eighth batch of national organized procurement agreements that have expired, with the purchasing volume based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual implementation date of the selected results [1] Group 2: Financial Impact - A total of 12 products from the company are expected to be selected, with projected sales revenue of 176.18 million yuan for 2024, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 3: Market Implications - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed purchasing volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and enhance the company's brand influence in the domestic market [1]

Core Viewpoint - Warner Pharmaceuticals (688799) has announced its participation in the national organized procurement for drugs whose agreements have expired, with 12 products expected to be selected for the continuation of procurement [2] Group 1: Financial Impact - The expected sales revenue from the selected products for 2024 is 176 million yuan, accounting for 12.47% of the company's total revenue for that year [2] - For the period of January to September 2025, the anticipated sales revenue is 192 million yuan, representing 17.69% of the company's revenue for that period [2]

格隆汇2月12日丨华纳药厂(688799.SH)公布，公司参加了国家组织集采药品协议期满品种接续采购办公 室（称"接续采购办公室"）组织的国家组织集采药品协议期满品种接续采购（称"本次接续采购"）。根 据接续采购办公室发布的《国家组织集采药品协议期满品种接续采购拟中选结果公示》，公司部分药品 拟中选本次接续采购，本次接续采购品种为第1-8批国家组织集采协议期满的品种，约定采购量以医药 机构填报各企业采购品种需求量为基数，按照中选价格梯度确定带量比例。采购周期自中选结果实际执 行日起至2028年12月31日。 公司本次拟中选的产品共计12个。公司上述拟中选产品2024年实现销售收入为17,618.05万元，占公司 2024年营业收入的12.47%；2025年1-9月实现销售收入为19,205.12万元，占公司2025年1-9月营业收入的 17.69%。采购周期中，医疗机构将优先使用本次药品接续采购中选药品，并确保完成约定采购量。若 公司后续签订采购合同并执行，将有利于扩大相关产品的销售规模，提高市场占有率，促进公司相关产 品国内市场的开拓，提升公司的品牌影响力。 ...

Core Viewpoint - Warner Pharmaceuticals announced participation in the national organized procurement for drugs, with 12 products expected to be selected, including Montmorillonite Powder and Mycophenolate Mofetil Capsules [1] Group 1: Procurement Details - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1] - The projected sales revenue for selected products in 2024 is 176.18 million yuan, accounting for 12.47% of the annual revenue [1] - For the period from January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the revenue during the same period [1] Group 2: Future Implications - If procurement contracts are signed and executed, it will expand the sales scale of the products [1] - There is uncertainty regarding the signing of procurement contracts and the execution of market sales [1]

Core Insights - The article highlights the transformation of Hunan's private economy, emphasizing the importance of technology, specialization, and integration for sustainable growth [1][26][49] Group 1: Technology as the Foundation - Hunan's private enterprises are increasingly focusing on technology and innovation as core competencies, moving beyond traditional manufacturing practices [3][29] - By 2025, private enterprises are expected to account for over 90% of all businesses in Hunan, contributing approximately 60% to the province's GDP [29] - Companies like Huazhu High-Tech are investing heavily in R&D, focusing on system-level development of equipment, materials, software, and processes rather than simple assembly [31][39] Group 2: Specialization and Craftsmanship - The concept of "specialization" is evident in companies like Warner Pharmaceutical, which emphasizes deep expertise and meticulous process improvements in drug development [37][46] - Warner Pharmaceutical's founder, Huang Bendong, advocates for a long-term commitment to research and development, reflecting a "craftsman spirit" in the pharmaceutical industry [37][46] - Water Sheep Co. has shifted from a marketing-driven approach to a research-driven model, focusing on product efficacy and quality through extensive R&D investments [33][41] Group 3: Integration for Growth - Water Sheep Co. exemplifies the integration of supply chain, data, and R&D capabilities, breaking down traditional barriers between branding, manufacturing, and consumer feedback [44][49] - Warner Pharmaceutical is adopting a cautious approach to integration, focusing on enhancing quality control and collaboration with research institutions while avoiding unrelated diversifications [46][48] - Huazhu High-Tech is not merely a technology supplier but aims to solve specific industry problems, fostering deeper collaborations with downstream clients [48][49]